Nonreplicating vaccinia vector efficiently expresses recombinant genes.
about
Susceptibility of different leukocyte cell types to Vaccinia virus infectionDeveloping Universal Influenza Vaccines: Hitting the Nail, Not Just on the HeadPoxvirus vectors as HIV/AIDS vaccines in humansThe evolution of poxvirus vaccinesMatrix and backstage: cellular substrates for viral vaccinesCritical role of perforin-dependent CD8+ T cell immunity for rapid protective vaccination in a murine model for human smallpoxHighly efficient induction of protective immunity by a vaccinia virus vector defective in late gene expressionAuthentic and chimeric full-length genomic cDNA clones of bovine viral diarrhea virus that yield infectious transcriptsGene Expression Driven by a Strong Viral Promoter in MVA Increases Vaccination Efficiency by Enhancing Antibody Responses and Unmasking CD8⁺ T Cell EpitopesExpression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVAVectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunityModified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseasesDifferent patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines.Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection.Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara.Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses.Viral vector-based influenza vaccines.Novel viral vectored vaccines for the prevention of influenza.Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses.Mutational analysis of the candidate internal fusion peptide of the avian leukosis and sarcoma virus subgroup A envelope glycoprotein.Incorporation of a lambda phage recombination system and EGFP detection to simplify mutagenesis of Herpes simplex virus bacterial artificial chromosomes.Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L.Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccinesDendritic cells are preferentially targeted among hematolymphocytes by Modified Vaccinia Virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo.Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategiesInduction of antibody responses to African horse sickness virus (AHSV) in ponies after vaccination with recombinant modified vaccinia Ankara (MVA).Chimeric plant virus particles administered nasally or orally induce systemic and mucosal immune responses in mice.Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes miceProtection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cellsNovel Nonreplicating Vaccinia Virus Vector Enhances Expression of Heterologous Genes and Suppresses Synthesis of Endogenous Viral ProteinsInduction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein.Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challengeComparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIVProtective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies.Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy.Vaccinia virus WR gene A5L is required for morphogenesis of mature virions.Immunogenicity of a human immunodeficiency virus (HIV) polytope vaccine containing multiple HLA A2 HIV CD8(+) cytotoxic T-cell epitopesRecombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region.Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus.Induction of mucosal homing virus-specific CD8(+) T lymphocytes by attenuated simian immunodeficiency virus
P2860
Q24801903-71085472-31CB-4C69-8822-58DCB9B181F3Q26783897-AC741013-B1C8-413D-AAA6-4030AB3D1190Q26995078-7B99A1B2-7101-4837-BA17-F0F3998904FEQ26995905-55C4647D-A557-4B3D-B23E-F009467BC30DQ27025941-F262F3F0-FBC0-426B-8200-84EB7376BDC7Q27346933-9C5C625A-B027-44C1-B0D4-4DBBCC460B96Q27469703-13F72B04-B800-4440-A660-A3190FB3CAABQ27480772-A64FEB82-03D3-4FFC-AC7E-B429A469F82CQ28647428-6D05745D-6C0D-46A2-8F49-B9D3C3B4AF58Q28727937-5A8BDC4D-2DBC-40D9-9A06-7C262FC2E5E1Q28743309-5A0FE549-E11F-4998-8A2D-C89319140CA6Q30209342-C57ADB51-3D3D-4B09-B4CF-D2D203C81EE3Q30330620-47AC1B6A-C558-463E-992F-749ABCA3C200Q30375489-92837EE5-EA05-48EA-8B6E-E339453A7345Q30375979-03AF703E-7622-4BBC-A75D-4F299403529CQ30382097-DBA047C1-4F66-4EB3-BEB8-0A924D816EAAQ30390938-445FA196-2700-4DD7-9E35-49C1E01FCF74Q30418570-1558700E-48E1-4153-A444-0F290F1F34F0Q30449492-A4D128B7-15B1-4310-90CD-E4BE3920FD76Q30453530-290C6D2D-9C67-48F9-85B1-325C15D525E3Q30831669-69D268F2-46F7-4B53-A30B-181C3A7F9596Q33187731-6A3D3375-6D6C-402B-8D44-A2626846AC97Q33210436-8F2FF644-020C-49B9-A619-09B09F3D0633Q33328336-91929AC1-0E6F-42F9-A362-C3DC154AC7A1Q33440600-1138646B-71D3-49E7-B23B-204DA0421C3AQ33471448-C00BE826-4196-40DB-A6F6-6E019974F3A8Q33640085-68CAF73E-CC31-4585-97EE-B062E29897C6Q33696283-4003741D-DB2A-46F7-BCD6-806356D50F88Q33737723-E1A1CBA7-657F-4566-9B7E-FC508E7D804DQ33770634-E23B4952-5FCC-4A71-BBB1-63E747E14813Q33784928-87CE287D-D0BB-4029-868E-E6D39FC4EF26Q33799497-3EFBF918-FFCB-4481-AF7A-EE84406B1AB8Q33800033-54EB65A9-9F99-45C2-8207-E864525C43E2Q33803714-9FCD4E2F-4991-4171-BB5A-13EAB058FC2DQ33808578-D1731BD0-CC09-462F-9275-E32D1A7E36EDQ33813478-A86A54F2-90E0-4F67-A40B-9B955DAE45F6Q33814863-EB14B06B-E77D-46F9-878B-55078AD68B6DQ33834543-61A246CA-5B76-4EBA-873B-93C7577F3051Q33843163-564FB75E-D07E-4AA6-A6D1-FB34D640695BQ33874561-FFE14E5C-19D2-48CE-9850-A14FDC685D7C
P2860
Nonreplicating vaccinia vector efficiently expresses recombinant genes.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh
1992年學術文章
@zh-hant
name
Nonreplicating vaccinia vector efficiently expresses recombinant genes.
@en
Nonreplicating vaccinia vector efficiently expresses recombinant genes.
@nl
type
label
Nonreplicating vaccinia vector efficiently expresses recombinant genes.
@en
Nonreplicating vaccinia vector efficiently expresses recombinant genes.
@nl
prefLabel
Nonreplicating vaccinia vector efficiently expresses recombinant genes.
@en
Nonreplicating vaccinia vector efficiently expresses recombinant genes.
@nl
P2860
P356
P1476
Nonreplicating vaccinia vector efficiently expresses recombinant genes.
@en
P2860
P304
10847-10851
P356
10.1073/PNAS.89.22.10847
P407
P577
1992-11-01T00:00:00Z